Skip to content

Trevi Therapeutics

US · TRVI #2810 by market cap Listed 2019
13.35 -0.37 -2.70%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 14.04 +2.33%
After-hours 13.35 0.00%
Overnight 13.46 -1.90%
19.5011.8813.352026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on TRVI?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -0.7% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 11.8% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Return on equity -30.2% Better than 13%
Return on invested capital -34.6% Better than 9%
Momentum C

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -25.7% Better than 23%
6-month return -5.5% Better than 46%
12-month return (ex latest month) 14.7% Better than 53%
Distance below 52-week high 34.0% Better than 36%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 19.7x Better than 98%
Debt to assets 0.4% Better than 96%
Interest coverage -11,984.3x Better than 0%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 107.6% Better than 85%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -2.20%
1M +4.05%
3M -26.85%
6M -3.82%
YTD +6.63%
1Y +25.35%
3Y +926.92%
5Y +1,159.43%

Key statistics

Price & volume

Prev close
13.72
Open
13.58
Day range
13.23 - 13.90
Avg price
13.47
Volume
2.09M
Turnover
28.14M
Amplitude
4.88%
52-week range
9.82 - 20.22

Valuation

P/E
-41.72
P/E (TTM)
-33.38
P/B
6.29
EPS
-0.32
Net profit
-45.62M
Net assets
302.80M

Share structure

Market cap
1.90B
Float cap
1.59B
Shares out
142.56M
Float shares
118.81M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2019-05-07
52-week range 34% of range
9.82 20.22

34.0% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+8.49M net over the window

Short interest

Shares short
16.86M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Trevi Therapeutics (TRVI)?

Trevi Therapeutics last traded at 13.35. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Trevi Therapeutics's market cap?

About 1.90B.

What is the P/E ratio of Trevi Therapeutics?

The trailing twelve-month P/E is -33.38. The Valuation tab shows it against the stock's own five-year range.

Does Trevi Therapeutics pay a dividend?

Trevi Therapeutics does not currently pay a regular dividend.

Is Trevi Therapeutics a buy according to analysts?

The consensus of 7 analysts is a Buy rating, with an average 12-month price target of 27.71, which implies 107.6% upside from the current price. This is not investment advice.

What is Trevi Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Trevi Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 20:02:43 · For reference only, not investment advice and not tailored to your situation.

Trevi Therapeutics discussion 0 comments

Add a comment